Literature DB >> 1485372

Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects.

M H de Vries1, M Raghoebar, I S Mathlener, J van Harten.   

Abstract

The pharmacokinetics of fluvoxamine maleate was studied in two separate studies in healthy young and elderly subjects. In a single and multiple oral dose administration study, six healthy young subjects received an initial 50 mg oral dose followed by 50 mg tablets every 12 h for 28 days. In a second study, 13 elderly subjects received 50 mg tablets every 12 h for 28 days. Fluvoxamine peak plasma concentrations were reached in approximately 5-6 h following oral administration of single and multiple 50 mg doses to healthy young and elderly volunteers. The area under the curve (AUC) of fluvoxamine tended to be larger following multiple (873 ng.h/ml) as compared to single-dose administration (652 ng.h/ml). Also the terminal half-life after chronic dosing (22 +/- 6 h) tended to be longer than after single dosing. Steady-state plasma levels were obtained within 10 days' administration. The pharmacokinetics of fluvoxamine in elderly healthy subjects were no different from those recorded in young subjects. These results suggest that it is not necessary to adjust the dosage of fluvoxamine in elderly depressed patients, on the basis of pharmacokinetic arguments. Independent of the age group, approximately 3% of a dose was recovered as unchanged drug in the urine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1485372     DOI: 10.1097/00007691-199212000-00010

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

3.  Non-linear fluvoxamine disposition.

Authors:  O Spigset; K Granberg; S Hägg; E Söderström; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

4.  Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.

Authors:  Rocco Orlando; Sara De Martin; Laura Andrighetto; Maura Floreani; Pietro Palatini
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

Review 5.  Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.

Authors:  S H Preskorn
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 6.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 7.  Overview of the pharmacokinetics of fluvoxamine.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 8.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 10.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.